ANDA 90221, held by Wockhardt Bio. Alfuzosin Hydrochloride.
As of Nov 22, 2026, ANDA 90221 (Alfuzosin Hydrochloride), held by Wockhardt Bio, was first approved by FDA on Aug 10, 2012, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 10, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alfuzosin Hydrochloride10MG · tablet, extended release;oral | Alfuzosin Hydrochloride | Discontinued |
| Sep 2, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 10, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters